-
O’Donnell DE, Milne KM, James MD, et al. Dyspnea in COPD: New mechanistic insights and management implications. Adv Ther. 2020;37(1):41-60.
-
Cooper CB, Dransfiels M. Primary care of the patient with chronic obstructive pulmonary disease-part 4: understanding the clinical manifestations of a progressive disease. Am J Med. 2008;121(7 Suppl):S33-45.
-
Mahler DA, Harver A. A factor analysis of dyspnea ratings, respiratory muscle strength, and lung function in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1992;145(2 Pt 1):467-70.
-
Slok AHM, Kotz D, van Breukelen G, et al. Effectiveness of the assessment of burden of COPD (ABC) tool on health-related quality of life in patients with COPD: a cluster randomised controlled trial in primary and hospital care. BMJ Open. 2016;6(7):e011519.
-
-
-
-
Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the Bold study): a population-based prevalence study. Lancet. 2007;370:741-50.
-
-
-
-
Zorginstituut Nederland. Zinnige Zorg Verbetersignalement | Zorgtraject van mensen met COPD. 2019;ICD-10: J40-J44.
-
Chapman KR, Mannino DM, Soriana JB, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J. 2006;27(1):188-207.
-
Wagena EJ, Zeegers MP, van Schayck CP, et al. Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease. Drug Saf. 2003;26(suppl 6):381-403.
-
-
Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1(suppl 6077):1645-8.
-
-
Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645-53.
-
MacNee W. ABC of chronic obstructive pulmonary disease: Pathology, pathogenesis, and pathophysiology. BMJ. 2006; 332(7551): 1202–1204.
-
O’Donnell R, Breen D, Wilson S, et al. Inflammatory cells in the airways in COPD. Thorax. 2006; 61(5): 448–454.
-
Wacker ME, Jörres RA, Karch A, et al. Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities. BMC Pulm Med. 2016;16(1):70.
-
Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122.
-
Johannessen A, Lehmann S, Omenaas ER, et al. Post-bronchodilator spirometry reference values in adults and implications for disease management. Am J Respir Crit Care Med. 2006;173:1316-25.
-
Mannino DM, Buist AS, Vollmer WM. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function? Thorax. 2007;62:237-41.
-
Van Schayck CP, Loozen HM, Wagena E, et al. Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. BMJ. 2002;324(7350):1370.
-
Slok AHM, Bemelmans TCH, Kotz D, et al. The assessment of the burden of COPD (ABC) scale: a reliable and valid questionnaire. J COPD 2016;13:431-8.
-
-
Van der Molen T, Willemse BWM, Schokker S, et al. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes. 2003;1:13.
-
Behandeling van Tabaksverslaving, herziene versie 2009. Utrecht: CBO, 2009.
-
Fastenau A, Van Schayck CP, Winkens B, et al. Effectiveness of an exercise training programme COPD in primary care: A randomized controlled trial. Respir Med.2020;165:105943.
-
Spruit MA, Burtin C, De Boever P, et al. COPD and exercise: does it make a difference? Breathe (Sheff). 2016;12(2): e38–e49.
-
Richtlijn Zuurstofbehandeling thuis. Utrecht: CBO, 2000.
-
Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Int Med. 1980;93:391-8.
-
Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines. American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127:335-71.
-
Hagedoorn P, Frijlink HW, de Boer AH. Longdepositie na pulmonale geneesmiddeltoediening bij COPD. Inhalator bepaalt effectiviteit. PW. 2011;9-10:32-5.
-
Van der Palen J, Klein JJ, van Herwaarden CL, et al. Multiple inhalers confuse asthma patients. Eur Respir J. 1999;14:1034-7.
-
Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374:1171-8.
-
Decramer M, Cooper CB. Treatment of COPD: the sooner the better. Thorax. 2010;65:837-41.
-
Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010;137:20-30.
-
Oba Y, Keeney E, Ghatehorde N, et al. Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta‐analysis. Cochrane Database of Systematic Reviews. 2018(12).
-
Watz H, Tetzlaff K, Wouters EFM, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. The Lancet Respiratory Medicine. 2016;4(5):390-398.
-
Calverly PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775-89.
-
Magnussen H, Lucas S, Lapperre T, et al. Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study. Respiratory research. 2021;22(1):1-4.
-
Schols AM, Wesseling G, Kester AD, et al. Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. Eur Respir J. 2001;17(3):337-42.
-
Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. COPD Clinical Research Network. N Engl J Med. 2011;365:689-98.
-
Verberkt CA, van den Beuken-van MH, Schols JM, et al. Effect of sustained-release morphine for refractory breathlessness in chronic obstructive pulmonary disease on health status: a randomized clinical trial. JAMA Internal Medicine. 2020;180(10):1306-14.
-
Fabbri LM, Hurd SS. GOLD Scientific Committee. Global strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur Respir J. 2003;22(suppl 1):1-2.
-
Jones PW. Triple therapy for chronic obstructive pulmonary disease. Am J Resp Crit Care Med. 2009;180:689-90.
-
Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med. 2009;180:741-50.
-
Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371:1285-94.
-
Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374:2222-34.
-
Schermer TR, Hendriks AJ, Chavannes NH, et al. Probability and determinants of relapse after discontinuation of inhaled corticosteroids in patients with COPD treated in general practice. Primary Care Respiratory Journal. 2004;13(1):48-55.
-
Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary dis-ease exacerbations with the dual bronchodilator QVA149 compared with glycopyrro-nium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. The lancet Respiratory medicine. 2013;1(3):199-209.
-
Chapman KR, Wedzicha JA, Roche N, et al. Improvement In Lung Function And Health Status With Indacaterol/Glycopyrronium Versus Salmeterol/Fluticasone In A Subgroup Of Patients With≥ 2 Exacerbations In The Previous Year: Results From The FLAME Study. InB47. LONG ACTING BRONCHODILATOR THERAPY IN COPD I. 2017 (pp. A3592-A3592). American Thoracic Society.
-
Magnussen H, Watz H, Kirsten A, et al. Stepwise withdrawal of inhaled corticosteroids in COPD pa-tients receiving dual bronchodilation: WISDOM study design and rationale. Respira-tory medicine. 2014;108(4):593-9.
-
Fens T, van der Pol S, Kocks JWH, et al. Economic impact of reducing inappropriate inhaled corticosteroid use in patients with COPD: ISPOR’s guidance on budget impact in practice. Value in Health. 2019; 22(10):1092-1102.
-
Van Schayck CP, Wesseling G, Schermer TR, et al. Stoppen met ICS-gebruik bij COPD-patiënten. TPO de Praktijk. 2019;14(5):32-4.
-
Van Schayck CP, Chavannes N, Kocks J. Terugdringen van onjuist ICS-gebruik bij COPD. Huisarts en Wetenschap. 2021;64(1):30-4.
-
Yang IA, Clarke MS, Sim EHA, et al. Inhaled corticosteroids for stable chronic ob-structive pulmonary disease. Cochrane Database Syst Rev Online. 2012;7:CD002991.
-
Bafadhel M, McKenna S, Terry S, et al. Acute exacerbati-ons of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;184(6):662–71.
-
Siva R, Green RH, Brightling CE, et al. Eosinophi-lic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007;29(5):906–13.
-
Pavord ID, Bafadhel M. Exhaled nitric oxide and blood eosinophilia: independent markers of preventable risk. J Allergy Clin Immunol. 2013;132(4):828–9.
-
Bafadhel M, Peterson S, De Blas MA, et al. Pre-dictors of exacerbation risk and response to budesonide in patients with chronic ob-structive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117–26.
-
Cazzola M, Rogliani P, Calzetta L, et al. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J. 2018;52(6):1801586.
-
Oshagbemi OA, Odiba JO, Daniel A, et al. Absolute blood eosinophil counts to guide inhaled corticosteroids therapy among patients with COPD: systematic review and meta-analysis. Curr Drug Targets. 2019;20(16):1679–0.
-
George L, Brightling CE. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis. 2016;7(1) 34–51.
-
Account
1
